Dabigatran etexilate is an oral prodrug; esterase hydrolysis in gut/liver/plasma yields active dabigatran, a reversible, competitive direct thrombin inhibitor that binds both free and fibrin-bound thrombin. Absorption from the gut requires an acidic microenvironment — hence the tartaric-acid pellet formulation and the tendency for dyspepsia. ~80% renal elimination makes creatinine clearance the dominant determinant of exposure. Specific reversal agent: idarucizumab.
Half-Life & Elimination Curve (PO: 13h)
Plasma (PO)t½ Decay (13h)Effect Site (ke0)
0×t½0h100%(0.142 mg/L)
1×t½13h50%(70.8 µg/L)
2×t½26h25%(35.4 µg/L)
3×t½39h12.5%(17.7 µg/L)
4×t½52h6.3%(8.85 µg/L)
5×t½65h3.1%(4.42 µg/L)
Elimination t½13h (PO)
Rate Constant (ke)0.0533 h⁻¹
Time to Peak (Tmax)3.98h
Est. Peak (Cmax)0.142 mg/L
Clearance (CL)3.2 L/h
97% Washout (5×t½)65h
Dosing Guidelines
Oral (PO): Typical 150 mg
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 7% · Volume of Distribution (Vd): 60 L · Absorption (ka): 0.7 h⁻¹ (t½ka ≈ 59m) [PMID 18076218]